ISRG stock trades at USD 506.88 intraday on 02 Mar 2026 as investors balance strong growth and a premium valuation. Intuitive Surgical, Inc. (ISRG) on NASDAQ continues to show revenue momentum after January earnings that beat estimates, while the market watches instrument sales and recurring service revenue. We assess fundamentals, technicals, analyst targets and an AI-driven price forecast to frame near-term opportunities and risks for US investors in this healthcare automation name.

ISRG stock market snapshot and momentum

Intuitive Surgical, Inc. (ISRG) trades on the NASDAQ in the United States with market cap USD 178.81 billion and daily volume about 1,570,742.00 shares. The intraday range is USD 501.40 to USD 511.88, with a 52-week high of USD 603.88 and low of USD 425.00. The 50-day average price is USD 532.54 and the 200-day average is USD 514.78, showing recent underperformance versus the shorter trend.

ISRG stock earnings and financials

ISRG reported fiscal quarter EPS USD 2.53, beating consensus and lifting trailing EPS to USD 8.05. Revenue growth ran near 18.8% year-over-year, reflecting strength in systems and instruments. Profit margins remain healthy with a net margin about 28.38% and operating cash flow per share USD 8.54, supporting reinvestment and services expansion.

ISRG stock valuation and key ratios

Valuation is elevated: price-to-earnings ratio stands at 62.55 and price-to-sales near 17.75. Return on equity is 16.39%, free cash flow yield about 1.39%, and price-to-book is 10.02. These metrics show premium pricing versus peers and justify attention to growth delivery and margin durability.

ISRG stock technicals and trading signals

Short-term technicals show neutral momentum: RSI 47.52 and MACD histogram slightly positive. ADX 33.36 signals a strong trend, while ATR 12.43 indicates moderate volatility. On balance, trading volume is below the 30-day average, with relative strength pressured since the 50-day moving average.

ISRG stock Meyka AI grade and forecast

Meyka AI rates ISRG with a score out of 100: 79.81 (Grade B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a 1-year target of USD 602.22, implying an upside of 18.82% versus the current USD 506.88, and a quarterly figure near USD 519.47. Forecasts are model-based projections and not guarantees.

ISRG stock risks and AI-era opportunities

Intuitive’s long-term opportunity rests on expanding the da Vinci platform, Ion diagnostics and software-enabled services that benefit from data and AI. Key risks include surgical reimbursement changes, competition on pricing and execution risk in international rollout. Insider selling and concentrated institutional ownership should factor into position sizing.

Final Thoughts

Key takeaways for ISRG stock: the company combines durable margins, recurring service revenue and AI-enabled surgical analytics with premium valuation. At USD 506.88 intraday, the stock trades at PE 62.55 and shows a near-term technical neutral stance. Meyka AI’s forecast model projects a 12-month target of USD 602.22, an implied upside of 18.82%, while a shorter monthly model level sits near USD 356.69, reflecting scenario risk. Investors should weigh strong revenue and free cash flow per share (USD 7.02) against rich multiples and trading volatility. We present this analysis using Meyka AI’s AI-powered market analysis platform; forecasts are model-based projections and not guarantees. For active traders focused on AI-driven medical tech, position size should reflect valuation risk and earnings cadence ahead of the next report on 21 Apr 2026.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.